Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a price target of €90.00. The company’s shares closed ...

TORINO, Italy--(BUSINESS WIRE)--Resalis Therapeutics announced today a strategic equity investment from Sanofi. The company intends to use the proceeds to accelerate the development of its lead ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

French pharmaceutical group Sanofi experienced a profitability boom in the third ... Tzield - for type 1 diabetes -, Sarclisa (multiple myeloma) and Rezurock, used in cases of graft-versus-host ...

Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...

Sanofi will keep a significant stake in the ... Another great milestone is the approval with Sarclisa in the US for adult patients with newly diagnosed multiple myeloma ineligible for transplantation.